ABOUT US
WHO WE ARE
Brazos Neuroscience specializes in developing and deploying advanced tests for the diagnosis and management of neurologic disease.
Our founders and leaders, Peter Bryant-Greenwood M.D. and Kevin P. Rosenblatt M.D., Ph.D. have 60+ years of experience in diagnostics including training at the National Institutes of Health and the Center for Biologics Evaluation and Research, FDA. They have enjoyed diverse academic and commercial careers including leadership roles at institutions such at UTSW Medical Center, the Brown Foundation for Molecular Medicine, National Jewish Health, and MD Anderson Cancer Center.
Brazos Neuroscience has the only objective Traumatic Brain Injury (TBI) laboratory test of its kind in the market. Through our proprietary NEURO-Trauma Assessment Test™ we are able to determine, using biomarkers found in blood, if a patient is suffering from a mild-to-moderate TBI in the acute, post-acute or chronic period.
Vision Statement
To revolutionize the field of neurological health by pioneering accessible, cutting-edge diagnostics that illuminate the path to recovery for those affected by traumatic brain injury, thereby shaping a future where every individual has the clarity and support to overcome the challenges of neural trauma.
Mission Statement
Brazos Neuroscience is dedicated to improving the quality of life for individuals suffering from traumatic brain injuries. With our groundbreaking NEURO-Trauma Assessment Test™ and a commitment to scientific excellence, we strive to provide clinicians and patients with precise, actionable insights to diagnose and manage mild to moderate TBIs. Leveraging advanced biomarker analysis and genetic insights, our mission is to deliver objective, reliable, and timely data for optimized care, fostering a new era of personalized medicine in neurology.